◆ NeutralRYETBGLC

RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

GlobeNewswire Inc.·
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.

Read Full Article at GlobeNewswire Inc. →
← Back to Financial Intelligence